HEALTHCARE DISPUTES

Litigation & Risk Management for Private Equity

DLA Piper's Healthcare Disputes Group provides private equity firms with comprehensive litigation and risk management strategies tailored to the complexities of healthcare investments. Our cross-disciplinary team—spanning regulatory, litigation, employment, and white-collar defense—helps PE firms navigate disputes, regulatory challenges, and compliance risks across their healthcare portfolios.

We work closely with our transactional teams to assess risks during due diligence, identify compliance gaps, and develop mitigation strategies to protect investments and maximize value. Whether defending portfolio companies in class actions, responding to government investigations, or proactively addressing potential liabilities ahead of a sale, our team delivers seamless, business-focused solutions. With deep experience advising PE-backed healthcare platforms, we help investors safeguard their assets and position their companies for long-term success.

Leading Firm
Healthcare Service Providers
The Legal 500 US 2025

Highly Regarded
Corporate Crime and Investigations
Chambers USA 2025

Powerhouse
Class Action Litigation
BTI Litigation Outlook 2025

"With one of the largest and most sophisticated teams of disputes lawyers globally, we can manage large-scale challenges efficiently around the world."

PROTECTING YOUR INTERSTS

Our approach

We provide private equity clients a “one-stop-shop” to service all healthcare disputes, from ERISA disputes to class actions amd multidistrict litigation to investigations and audits. Our lawyers leverage their extensive industry knowledge, experience, and tenacity on the front end to accurately assess the issues our clients face and obtain results that align with their business objectives.

Healthcare Litigation

Private equity’s growing presence in healthcare brings heightened litigation risks, especially as cost pressures intensify. Investors pursuing aggressive revenue strategies—such as out-of-network billing or high-acuity procedures—may face increased scrutiny from regulators and payors. Reimbursement disputes will escalate as Medicare spending cuts drive providers to seek higher commercial rates. Additionally, AI-driven billing and treatment decisions could trigger legal challenges, particularly around claims adjudication and compliance. Proactively managing regulatory and reimbursement risks will be critical for private equity investors in healthcare.

Healthcare Investigations

Government agencies are intensifying their scrutiny of healthcare organizations through aggressive investigations targeting kickback violations, billing fraud, practice violations, antitrust issues, and self-referral violations. With substantial penalties at stake and enforcement expected to continue under the new administration, risks now extend beyond traditional providers to include private equity firms and other investors with significant healthcare ownership stakes.

Medicare & Medicaid Audits

Increased scrutiny of enrollment data and evolving denial tactics create operational and financial risks that can threaten portfolio company stability. At the same time, agencies are relying on sub-regulatory guidance, adding uncertainty around compliance obligations and enforcement. We help investors by identifying potential regulatory pitfalls and structuring proactive strategies to mitigate risk.

Brian Benjet

Partner
Philadelphia
T +1 215 656 3311
Email

Ardith Bronson

Partner
Miami
T +1 305 423 8562
Email

Eric Christofferson

Partner
Boston
T +1 617 406 6089
Email

Tracy Weir

Partner
Washington, DC
T +1 202 799 4032
Email

Deborah Samenow

Of Counsel
Washington, DC
T +1 202 799 4497
Email